<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15194">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00194129</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH050165</org_study_id>
    <secondary_id>R01MH050165</secondary_id>
    <nct_id>NCT00194129</nct_id>
  </id_info>
  <brief_title>Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder</brief_title>
  <official_title>A Randomized, Double Blind Comparison of Lithium Monotherapy Versus Lithium Plus Divalproex for the Outpatient Management of Hypomania/Mania in Patients With Rapid Cycling Bipolar Disorder Comorbid With Substance Abuse/Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Case Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Case Medical Center</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the efficacy and safety of combination therapy with divalproex and
      lithium for treating mania in people with rapid cycling bipolar disorder and a substance
      abuse disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Longitudinal Evaluation of the Efficacy and Safety of Divalproex and Lithium in Dual
      Diagnosis Bipolar Rapid Cycling: This study recruits males and females age 18 and older who
      currently meet diagnostic criteria for rapid cycling bipolar disorder (type I or II) and who
      have met the criteria for substance abuse or dependence of cocaine, marijuana and/or alcohol
      within the past six months. Patients are initially stabilized on dual therapy of lithium and
      depakote and then randomly assigned to double-blind treatment with either lithium
      monotherapy or continued dual therapy. Patients remain in the study for six months or until
      they experience a relapse. Patients in this study are required to bring a friend or family
      member to all study visits as well as attend chemical dependency services. This study is
      sponsored by the NIMH. Subjects receive study-related care at no cost.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1997</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to Treatment for Emerging Symptoms of a Mood Relapse</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment for Emerging Symptoms of a Manic/Hypomanic/Mixed Episode</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment for Emerging Symptoms of a Depressive Episode</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rate of Alcohol Use Disorders After Open-label Treatment With Lithium and Divalproex</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rate of Cannabis Use Disorders After Open-label Treatment With Lithium and Divalproex</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rate of Cocaine Use Disorders After Open-label Treatment With Lithium and Divalproex</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Lithium plus Divalproex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to the combination group were continued on lithium and blinded divalproex.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lithium plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients assigned to lithium monotherapy underwent divalproex-placebo substitution at a rate of 250 mg decrements every week until discontinued.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <description>Lithium monotherapy was initiated at 300 mg twice daily and titrated over 3-6 weeks to minimum blood levels of 0.8 meq/L.</description>
    <arm_group_label>Lithium plus Divalproex</arm_group_label>
    <arm_group_label>Lithium plus placebo</arm_group_label>
    <other_name>Lithium Carbonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Divalproex</intervention_name>
    <description>Divalproex was then initiated at 250 mg twice daily and increased over 3-6 weeks to minimum blood levels of 50 ug/ml.</description>
    <arm_group_label>Lithium plus Divalproex</arm_group_label>
    <other_name>Valproic Acid</other_name>
    <other_name>Depakote</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be included in this study, patients will be required to be either acutely
             hypomanic or manic as defined by the Diagnostic and Statistical Manual -IV (DSM-IV)
             and meet criteria for current substance abuse and/or dependence disorder within the
             last six months.

          -  Must have 4 or more episodes in the immediate 12 months prior to study entry.

          -  Males or females 16 - 65 years of age.

          -  A score of 60 or less on the Global Assessment Scale.

          -  Have no medical illness precluding the use of lithium or divalproex.

        Exclusion Criteria:

          -  Patients who have had intolerable side effects to lithium levels 0.8 meq/L or
             divalproex levels of 50 ug/ml. Patients who have been completely non-responsive to
             lithium in the past will be excluded, whereas patients who have had partial responses
             to lithium will be permitted into the study.

          -  Patients with a prior history of seizure disorder, cerebral vascular disease,
             structural brain damage from trauma, clinically significant focal neurological
             abnormalities, EEG abnormalities with frank paroxysmal activity or a previous CT/MRI
             scan of the brain with gross structural abnormalities.

          -  Patients who require anticoagulant drug therapy.

          -  Patients who have uncontrolled gastrointestinal, renal, hepatic, endocrine,
             cardiovascular, pulmonary, immunological or hematological disease. Patients with
             alcohol-related liver disease as reflected by diffuse elevations in liver functions
             tests exceeding the upper limits of the normal range by 50% will be excluded.

          -  Patients who are pregnant or plan to become pregnant during the study.

          -  Patients who have received haloperidol decanoate or fluphenazine decanoate within the
             last 10 weeks.

          -  Patients who have a central nervous system (CNS) neoplasm, uncontrolled metabolic,
             demyelinating or progressive disorder; active CNS infection; or any progressive
             neurological disorder.

          -  Patients who are taking exogenous steroids.

          -  Patients who do not meet criteria for substance abuse or dependence.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph R Calabrese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University / University Hospitals of Cleveland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 4, 2013</lastchanged_date>
  <firstreceived_date>September 13, 2005</firstreceived_date>
  <firstreceived_results_date>November 4, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Case Medical Center</investigator_affiliation>
    <investigator_full_name>Joseph Calabrese, MD</investigator_full_name>
    <investigator_title>Director, Mood Disorders Program</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lithium</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at the outpatient Mood Disorders Program of Case Western Reserve University/University Hospitals Case Medical Center between October 1997 and October 2006.</recruitment_details>
      <pre_assignment_details>Patients meeting stabilization criteria for a minimum of 4 consecutive weeks were eligible for random assignment to double-blind maintenance treatment. Patients not meeting these criteria by 24 weeks were discontinued from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lithium Plus Divalproex</title>
        </group>
        <group group_id="P2">
          <title>Lithium Plus Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lithium Plus Divalproex</title>
        </group>
        <group group_id="B2">
          <title>Lithium Plus Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="37.1" spread="10.9"/>
                <measurement group_id="B2" value="40" spread="10.6"/>
                <measurement group_id="B3" value="38.4" spread="10.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="21"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Illness Type</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Bipolar I disorder</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Bipolar II disorder</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Treatment for Emerging Symptoms of a Mood Relapse</title>
        <time_frame>Up to 6 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Lithium Plus Divalproex</title>
          </group>
          <group group_id="O2">
            <title>Lithium Plus Placebo</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Treatment for Emerging Symptoms of a Mood Relapse</title>
            <units>weeks</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17.8" lower_limit="12.8" upper_limit="27.6"/>
                  <measurement group_id="O2" value="15.9" lower_limit="11.0" upper_limit="22.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment for Emerging Symptoms of a Manic/Hypomanic/Mixed Episode</title>
        <time_frame>Up to 6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment for Emerging Symptoms of a Depressive Episode</title>
        <time_frame>Up to 6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Rate of Alcohol Use Disorders After Open-label Treatment With Lithium and Divalproex</title>
        <time_frame>Baseline to Month 6</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Rate of Cannabis Use Disorders After Open-label Treatment With Lithium and Divalproex</title>
        <time_frame>Baseline to Month 6</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Rate of Cocaine Use Disorders After Open-label Treatment With Lithium and Divalproex</title>
        <time_frame>Baseline to Month 6</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lithium Plus Divalproex</title>
        </group>
        <group group_id="E2">
          <title>Lithium Plus Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Polyuria/Polydipsia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Sexual Dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Cognitive Dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Kemp, MD</name_or_title>
      <organization>UHCMC Mood Disorders Program</organization>
      <phone>216-844-2865</phone>
      <email>David.Kemp@UHhospitals.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
